Factors related to human papillomavirus vaccination

doi:10.3877/cma.j.issn.1674-0785.2017.13.008

Abstract

Abstract:

Cervical cancer is one of the most common gynecological malignant neoplasms, with people aged between 50 and 55 years having a high incidence. It is the only cancer type whose cause has already been clarified so far. Human papillomavirus (HPV), which is transmitted mainly through sexual transmission, is closely related to the development and progression of cervical cancer and is the most important reason for the occurrence of cervical cancer. Since the cause of cervical cancer is clear and its screening method is relatively perfect, it is a preventable tumor. Therefore, HPV vaccination is an important measure to prevent or treat human papillomavirus infection and reduce the incidence of cervical cancer.

Key words: Human papillomavirus, Human papillomavirus vaccine, Cervical cancer, Prevention, Acceptability

Dongli Guo, Zanhong Wang. Factors related to human papillomavirus vaccination[J]. Chinese Journal of Clinicians(Electronic Edition), 2017, 11(13): 1997-2001.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlcyszz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0785.2017.13.008

https://zhlcyszz.cma-cmc.com.cn/EN/Y2017/V11/I13/1997

References 54

[1]	Ferlay J, Soerjomatarm I, Dikshit R, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 [J]. Int J Cancer, 2015, 136(5): E359-86.
[2]	Weinstock H, Berman S, Cates W Jr. Sexually transmitted diseases among American youth: incidence and prevealence estimates, 2000 [J]. Perspect Sex Reprod Health, 2004, 36(1): 6-10.
[3]	赵超，魏丽惠. HPV疫苗的临床应用价值 [J]. 国际生殖健康/计划生育杂志, 2015, 34(6): 462-466.
[4]	宋敬东，王健伟，韩金祥, 等. 人乳头瘤病毒疫苗的研究进展. 中国生物工程杂志, 2007, 27(4): 104-109.
[5]	Cates W Jr. Estimates of the incidence and prevalence of sexually transmitted diseases in the United States. American social health association panel [J]. Sex Transm Dis, 1999, 26(4 Suppl): S2-7.
[6]	Revzina NV, Diclemente RJ. Prevalence and incidence of human papillomavirus infection in women in the USA: a systematic review [J]. Int J STD AIDS, 2005, 16(8): 528-537.
[7]	Hariri S, Unger ER, Sternberg M, et al. Prevalence of genital human papillomavirus among females in the United States, the National Health And Nutrition Examination Survey, 2003-2006 [J]. J Infect Dis, 2011, 204(4): 566-573.
[8]	Kirby T. FDA approves new upgarded Gardasil 9 [J]. Lancet Oncol, 2014, 16(2): e56.
[9]	Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus(HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types(PATRICIA): final analysis of a double-blind, randomised study in young women [J]. Lancet, 2009, 374(9686): 301-314.
[10]	Munoz N, Manalastas R Jr, Pitisuttithum P, et al. Safety, immunogenicity, and efficacy of quadrivalent human papilloma-virus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial [J]. Lancet, 2009, 373(9679): 1949-1957.
[11]	Marlow LA, Zimet GD, McCaffery KJ, et al. Knowledge of human papillomavirus(HPV) and HPV vaccination: an international comparison [J]. Vaccine, 2013, 31(5): 763-769.
[12]	Marek E, Dergez T, Rebek-Nagy G, et al. Effect of an educational intervention on Hungarian adolescents′ awareness, beliefs and attitudes on the prevention of cervical cancer [J]. Vaccine, 2012, 30(48): 6824-6832.
[13]	Bowyer HL, Marlow LA, Hibbitts S, et al. Knowledge and awareness of HPV and the HPV vaccine among young women in the first routinely vaccinated cohort in England [J]. Vaccine, 2013, 31(7): 1051-1056.
[14]	World Health Organization. Human papillomavirus vaccines: WHO position paper, October 2014 [J].Wkly Epidemiol Rec, 2014, 89(43): 465-491.
[15]	Patel PR, Berenson AB. Sources of HPV vaccine hesitancy in parents [J]. Hum Vaccin Immunother,2013, 9(12): 2649-53.
[16]	Centers for Disease Control and Prevention. Human papillomavirus vaccination coverage among adolescent girls, 2007-2012, and postlicensure vaccine safety monitoring, 2006-2013-United States [J]. Weekly, 2013, 62(29): 591-595.
[17]	Licht AS, Murphy JM, Hyland AJ, et al. Is use of the human papillomavirus vaccine among female college students related to human papillomavirus knowledge and risk perception? [J]. Sex Transm Infect, 2010, 86(1): 74-78.
[18]	Lindley LL, Elkind JS, Landi SN, et al. Receipt of the Human Papillomavirus Vaccine Among Female College Students in the United States, 2009 [J]. J Am Coll Health, 2013, 61(1): 18-27.
[19]	Bernat DH, Gerend MA, Chevallier K, et al. Characteristics Associated With Initiation of the Human Papillomavirus Vaccine Among a National Sample of Male and Female Young Adults [J]. J Adolesc Health, 2013, 53(5): 630-636.
[20]	Williams WW, Lu PJ, Saraiya M, et al. Factors associated with human papillomavirus vaccination among young adult women in the United States [J]. Vaccine, 2013, 31(28): 2937-2946.
[21]	Chou B, Krill LS, Horton BB, et al. Disparities in human papillomavirus vaccine completion among vaccine initiators [J]. Obstet Gynecol, 2011, 118(1): 14-20.
[22]	Tan W, Viera AJ, Rowe-West B, et al. The HPV vaccine: Are dosing recommendations being followed? [J]. Vaccine, 2011, 29(14): 2548-2554.
[23]	Rondy M, van Lier A, van de Kassteele J, et al. Determinants for HPV vaccine uptake in the Netherlands: a multilevel study [J]. Vaccine, 2010, 28(9): 2070-2075.
[24]	Dorleans F, Giambi C, Dematte L, et al. The current state of introduction of human papillomavirus vaccination into national immunisation schedules in Europe: first results of the VENICE2 2010 survey [J]. Euro Surveill, 2010, 15(47): 19730.
[25]	Lenselink CH, Gerrits MM, Melchers WJ, et al. Parental acceptance of human papillomavirus vaccines [J]. Eur J Obstet Gynecol Reprod Biol, 2008, 137(1): 103-107.
[26]	Zhang SK, Pan XF, Wang SM, et al. Perceptions and acceptability of HPV vaccination among parents of young adolescents: A multicenter national survey in China [J]. Vaccine, 2013, 31(32): 3244-3249.
[27]	Akanbi OA, Lyanda A, Osundare F, et al. Perceptions of Nigerian women about human papilloma virus, cervical cancer, and HPV vaccine [J]. Scientifica(Cario), 2015, 2015: 285702.
[28]	Brinth L, Theibel AC, Pors K, et al. Suspected side effects to the quadrivalent human papilloma vaccine [J]. Dan Med J, 2015, 62(4): A5064.
[29]	赵超，魏丽惠. HPV疫苗的安全性问题 [J]. 实用妇产科杂志, 2010, 26(3): 174-177.
[30]	Global Advisory Committee on Vaccine Safety, 2-3 December2015 [N]. Wkly Epid Rec, 2016, 91(3): 21-31.
[31]	Aqosti JM, Goldie SJ. Introducing HPV vaccine in developing countries-key challenges and issues [J]. N Engl J Med, 2007, 356(19): 1908-1910.
[32]	GAVI injects new life into HPV vaccine rollout [R]. Lancet, 2013, 381(9879): 1688.
[33]	杨瑾，许璐洁，徐蕾,等. 西安非医学专业女大学生对HPV和HPV疫苗的认知 [J]. 中国妇幼保健研究, 2016, 27(8): 923-925.
[34]	李静，屠铮，赵超,等. 北京市社区妇女人乳头瘤病毒感染率及其对HPV和疫苗认知情况的调查分析 [J]. 中国肿瘤, 2008, 17(3): 168-172.
[35]	Franceschi S, Plummer M, Clifford G, et al. Differences in the risk of cervical cancer and human papillomavirus infection by education level [J]. Br J Cancer, 2009, 101(5): 865-870.
[36]	Zhao FH, Lin MJ, Chen F, et al. Performance of high-risk human papillomavirus DNA testing as a primary screen for cervical cancer: a pooled analysis of individual patient data from 17 population-based studies from China [J]. Lancet Oncol, 2010, 11(12): 1160-1171.
[37]	Li J, Kang LN, Li B, et al. Effect of a group educational intervention on rural Chinese women′s knowledge and attitudes about human papillomavirus(HPV) and HPV vaccines [J]. BMC Cancer, 2015, 15: 691.
[38]	曾晓敏，任泽舫，魏雪灵, 等. 中山大学本科生对HPV及疫苗认知的调查 [J]. 现代预防医学, 2015, 42(10): 1822-1825.
[39]	Centers for Disease Control and Prevention. FDA licensure of quadrivalent human papillomavirus vaccine(HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices(ACIP)[R]. MMWR Morb Mortal Wkly Rep, 2010, 59(20): 630-632.
[40]	Brabin L, Roberts SA, Stretch R, et al. A survey of adolescent experiences of human papillomavirus vaccination in the Manchester study [J]. Br J Cancer, 2009, 101(9): 1502-1504.
[41]	Robbins SC, Bernard D, McCaffery K, et al. ″I just signed″: Factors influencing decision-making for school-based HPV vaccination of adolescent girls [J]. Health Psychol, 2010, 29(6): 618-625.
[42]	Zimet GD, Mays RM, Sturm LA, et al. Parental attitudes about sexually transmitted infection vaccination for their adolescent children [J]. Arch Pediatr Adolesc Med, 2005, 159(2): 132-137.
[43]	唐良萏，冷若冰. 人乳头瘤病毒的临床应用 [J]. 实用妇产科杂志, 2013, 29(3): 172-174.
[44]	Etter DJ, Zinet GD, Rickert VI. Human papillomavirus vaccine in adolescent women: a 2012 update [J]. Curr Opin Obster Gynecol, 2012, 24(5): 305-310.
[45]	Reindl BM, Brown C. Religion and preventative health care utilization among the elderly [J]. Soc Sci Med, 2004, 58(1): 109-118.
[46]	Schiller PL, Levin JS. Is there a religious factor in health care utilization? A review [J]. Soc Sci Med, 1988, 27(12): 1369-1379.
[47]	Rachel C, Shelton, Anna C, et al. HPV vaccine decision-making and acceptance: does religion play a role? [J]. J Relig Health, 2013, 52(4): 1120-1130.
[48]	Constantine NA, Jerman P. Acceptance of human papillomavirus vaccination among californian parents of daughters: a representative statewide analysis [J]. J Adolesc Health, 2007, 40(2): 108-115.
[49]	Bernat DH, Harpin SB, Eisenberg ME, et al. Parental Support for the Human Papillomavirus Vaccine [J]. J Adolesc Health, 2009, 45(5): 525-527.
[50]	Patel PR, Berenson AB. The internet′s role in HPV vaccine education [J]. Hum VaccinImmunother, 2014, 10(5): 1166-1170.
[51]	Habel MA, Liddon N, Stryker JE. The HPV vaccine: a content analysis of online news stories [J]. J Womens Health, 2009, 18(3): 401-407.
[52]	Kelly BJ, Leader AE, Mittermaier DJ, et al. The HPV vaccine and the medial: how has the topic been covered and what are the effects on knowledge about the virus and cervical cancer? [J]. Patient EducCouns, 2009, 77(2): 308-313.
[53]	Hughes J, Cates JR, Liddon N, et al. Disparities in how parents are learning about the human papillomavirus vaccine [J]. Cancer Epidemiol Biomarkers Prev, 2009, 18(2): 363-372.
[54]	Boyer C, Selby M, Scherrer JR, et al. The Health On the Net Code of Conduct for medical and health Websites [J]. Comput Biol Med, 1998, 28(5): 603-610.

Please choose a citation manager

Content to export